LAM
ABBV icon

L2 Asset Management’s AbbVie ABBV Stock Holding History

L2 Asset Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.47M Sell
9,799
-2,816
-22% -$606K 0.26% 87
2026
Q1 		$2.74M Sell
12,615
-1,417
-10% -$314K 0.26% 86
2025
Q4 		$3.21M Sell
14,032
-1,687
-11% -$384K 0.43% 66
2025
Q3 		$3.64M Sell
15,719
-4,609
-23% -$939K 0.53% 54
2025
Q2 		$3.77M Buy
20,328
+2,296
+13% +$427K 0.62% 53
2025
Q1 		$3.78M Buy
18,032
+3,404
+23% +$662K 0.77% 46
2024
Q4 		$2.6M Buy
14,628
+140
+1% +$25.7K 0.57% 54
2024
Q3 		$2.86M Buy
14,488
+1,936
+15% +$361K 0.78% 42
2024
Q2 		$2.15M Buy
12,552
+5,918
+89% +$980K 0.65% 46
2024
Q1 		$1.21M Buy
6,634
+1,692
+34% +$292K 0.4% 65
2023
Q4 		$766K Buy
4,942
+4,576
+1,250% +$667K 0.31% 74
2023
Q3 		$902K Sell
366
-11,650
-97% -$1.71M 0.42% 68
2023
Q2 		$1.6M Buy
12,016
+1,673
+16% +$245K 0.78% 44
2023
Q1 		$1.65M Sell
10,343
-1,163
-10% -$178K 0.91% 33
2022
Q4 		$1.86M Hold
11,506
– – 1.16% 28
2022
Q3 		$1.54M Buy
11,506
+407
+4% +$58.4K 1.06% 35
2022
Q2 		$1.7M Buy
11,099
+1,623
+17% +$248K 1.23% 31
2022
Q1 		$1.54M Buy
9,476
+4,213
+80% +$612K 0.88% 39
2021
Q4 		$713K Buy
5,263
+1,254
+31% +$148K 0.5% 58
2021
Q3 		$432K Sell
4,009
-960
-19% -$110K 1.09% 40
2021
Q2 		$560K Sell
4,969
-1,217
-20% -$137K 0.52% 61
2021
Q1 		$669K Sell
6,186
-5,121
-45% -$548K 0.69% 54
2020
Q4 		$1.21M Sell
11,307
-2,313
-17% -$222K 0.83% 38
2020
Q3 		$1.19M Sell
13,620
-12,812
-48% -$1.21M 0.96% 37
2020
Q2 		$2.6M Buy
26,432
+764
+3% +$67.3K 2.35% 14
2020
Q1 		$1.96M Buy
25,668
+7,223
+39% +$615K 2.2% 19
2019
Q4 		$1.63M Buy
+18,445
New +$1.53M 1.43% 34

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

L2 Asset Management's ABBV Position: Q2 2026 in Review

L2 Asset Management reduced its AbbVie (ABBV) stake by 22% in Q2 2026, selling an estimated $606K and leaving 9,799 shares worth $2.47M. The position accounts for 0.26% of the portfolio, ranked #87.

L2 Asset Management first reported a position in ABBV in Q4 2019 and has held it in 27 quarters since. The position peaked at $3.78M in Q1 2025. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • L2 Asset Management held 9,799 shares of AbbVie worth $2.47M as of Q2 2026.
  • L2 Asset Management sold 2,816 AbbVie shares in Q2 2026, an estimated $606K.
  • AbbVie made up 0.26% of L2 Asset Management's portfolio in Q2 2026, its #87 holding.
  • L2 Asset Management first reported a position in AbbVie in Q4 2019 and has held it in 27 quarters since.
  • L2 Asset Management's AbbVie position peaked at $3.78M in Q1 2025.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on L2 Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.